Checkpoint proteins in patients with precancer and cervical cancer

The efficiency of immuno-oncological drugs in treatment cervical cancer is not high. The research of new immunological targets in cervical cancer is actual. The aim was to study the local level of checkpoint proteins of immune cycle in patients with cervical cancer of different stages (sCD25, 4-1BB, B7.2, TGF-b1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9, sCD27, PD-L2). Materials and research methods. The objects of study were the patients with precancer (n=13) and cervical cancer (n=49). The control group consisted of 13 gynecologically healthy women. The material of study was cervical epithelium obtained by cervical brush. The research method was flow cytometry. Test parameters: sCD25, 4-1BB, B7.2, TGF-b1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9, sCD27, PD-L2. Statistical analysis of the data was carried out using nonparametric statistics using the Mann - Whitney U-test. The results of the study. The levels of sCD25, B7.2, PDL1, Tim-3, sCD27, PD-L2 were increased in the comparison groups relation to the control (p <0.05). The differential criterion for invasive cervical cancer may be an increase in the level of LAG-3 in the cervical epithelium by 43% (p <0.05).The levels of PD-L1, PD-1, sCD27 and PD-L2 were increased opposite the levels LAG-3 and Galectin-9 were decreased in patients with metastatic cervical cancer(p <0.05).